It was a bad day for President Donald Trump. His former lawyer pleaded guilty in New York. His former campaign manager was found guilty in Virginia. There's no word on whether either man will seek leniency by cooperating with Special Counsel Robert Mueller and his probe of potential collusion with Russia, but it's likely to be a topic of conversation. —David E. Rovella Here are today's top storiesTexas spent years saving money at the expense of students who needed special education. Then the U.S. stepped in. Now the state is on the hook for billions of dollars to make things right. Russia is at it again, Microsoft said. The company seized web domains created by cyber-attackers it said are linked to that country's military and aimed at manipulating midterm elections. The Trump administration said 1,600 more Americans will die every year under the Environmental Protection Agency's plan to loosen pollution rules governing power plants. You’ve probably heard that it’s the longest bull market ever. You’ve probably also heard that it isn’t. What’s the story? We're here to tell you what's true, and what's not. While anti-immigrant groups in the U.S. and Europe clamor for walls and deportation, in Sweden immigrants are making the economy hum, Bloomberg Businessweek reports. Brexit negotiations will take place “continuously” as time runs out on Britain's scramble to get a seat before the music stops. What's Joe Weisenthal thinking about? The Bloomberg news director is mulling what effect Trump's unorthodox statements about the Fed may have in the long run. What you'll need to know tomorrowThe S&P 500 hit a new intraday high as another stock market record draws near.The Fed minutes coming this week may shed light on rate hike frequency.Bad news for Brazil's market friendly candidates is bad news for its currency.Democratic senators are angry about alleged Russian hacking of the midterms. Startups are worried Trump's global trade war will put worms in the next Apple.United is testing lie-flat seats for its longest domestic routes.This tycoon is locked in a battle with Tata to access a $17 billion fortune. Sponsored by Purdue Pharma We make prescription opioids. And we want to limit their use. For over 25 years, we’ve developed opioid medications for patients with chronic pain, and we are acutely aware of the public health risks they can create. As such, we believe the country needs a new approach to prescribing opioids. What you'll want to read tonightDreaming of being a wine collector with a killer cellar but don’t know how? We understand. The whole prospect of assembling the wines can be a shopping hassle requiring time-consuming research and way too many picky decisions. But you’re in luck. Don’t miss this exclusive offer. Subscribe to Bloomberg All Access today and get unmatched global news coverage, two premium newsletters, The Bloomberg Open and The Bloomberg Close, Bloomberg Live events access and much more. The global economy is at an inflection point. Sign up for the Turning Points newsletter to be one of the first to receive weekly insights—and solutions—on climate, tech and trade from Andrew Browne and leading experts. Download the Bloomberg app: It's available for iOS and Android. |